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Systematic mixed study review of non-pharmacological management of 
neonatal abstinence syndrome 
 
ABSTRACT 
 
Background: Neonatal abstinence syndrome is a multi-system disorder resulting 
from exposure to maternal addictive substance use in pregnancy. Withdrawal is 
characterized by neonatal tremors, feeding difficulties and sleep disruption. The aim 
of this systematic review is to explore the non-pharmacological management of 
infants at risk of neonatal abstinence syndrome following prenatal exposure.  
Methods: A systematic mixed study review was conducted. A search of CINAHL, 
MEDLINE, AMED, PsycArticles, PsycInfo and Web of Science was performed for 
relevant articles published between January 2007 and June 2018. Quantitative and 
qualitative data were extracted, and thematic analysis undertaken. The findings were 
synthesized as a narrative summary.  
Results: Fourteen studies were included in the review of which nine were quality 
improvement initiatives and five explored complementary therapies. The most 
common components of non-pharmacological management were consolation 
therapy and rooming-in of mother and baby.  Implementation strategies incorporated 
family integrated care and practitioner training in the evaluation of neonatal 
withdrawal.  When non- pharmacological management was applied there was a 
reduction in the need for pharmacotherapy and a shorter hospital stay for neonates. 
Potential barriers to effective management included unreliable assessment tools, 
judgemental practitioner attitudes and limited breastfeeding promotion.  
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Conclusion: Providing and optimizing non-pharmacological management for the 
infant at risk of neonatal abstinence syndrome improves outcomes by reducing their 
length of hospital stay and the need for pharmacotherapy.    
Keywords: ‘neonatal abstinence syndrome', 'non-pharmacological care', 'mixed study 
review’ 
 
INTRODUCTION 
Neonatal abstinence syndrome (NAS) is a multisystem disorder of adverse neuro-
behaviour (1).  It results from the exposure of the fetus to maternal use of illicit or 
prescription addictive substances during pregnancy. Following the abrupt 
discontinuation of these compounds at birth the neonate is placed at risk of 
withdrawal symptoms.     The severity of the withdrawal process is variable but it is 
characterized by tremors, feeding difficulties and inconsolability with the potential of 
respiratory distress, seizures and death if left untreated (2).   
The documented prevalence of NAS varies significantly between institutions and the 
number of neonates at risk of withdrawal is difficult to predict (3).  This stems from a 
number of factors including the hesitancy of women to self-report their illicit 
substance use due to its illegal nature, a fear of stigma and child custody concerns 
(2).   Furthermore, not all exposed neonates will demonstrate signs of withdrawal 
leading to under diagnosis (4).   Recent data, however, indicates an increasing 
incidence of substance use in pregnancy with the number of infants at risk of NAS 
estimated at 2–6/1000 per live births (3, 5).  
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Current guidelines recommend in-hospital observation and non-pharmacological or 
supportive management for infants at risk of NAS (6). The aim of this is to alleviate 
the severity and escalation of withdrawal symptoms in order to support the infant to 
maintain adequate hydration, nutrition and rest.  Supportive management 
incorporates consolation strategies of swaddling, non-nutritive sucking and skin -to-
skin contact; minimizing environmental stimuli from light, noise and activity, and 
breastfeeding promotion (2,7).     
When   non-pharmacological measures are insufficient to contain withdrawal 
severity, pharmacotherapy of an opiate and sedation medication is recommended 
(8,9).  While pharmacotherapy will ease the withdrawal severity, there are 
disadvantages associated with it use.  The long-term impact of medication on the 
neonate is unknown and the gradual weaning process results in a lengthy hospital 
stay. This prolonged separation of mother and infant brings the potential of disrupted 
bonding (6) and the increased period of hospitalization incurs significant health care 
costs (10).  
Effective non-pharmacological care offers a clear benefit of minimizing the need for 
pharmacotherapy. Yet despite existing evidence, provision of non-pharmacological 
care is primarily based on practitioner experience or local conditions and its 
implementation within clinical practice is reported as variable (11,12).      Previous 
research also suggests that the diversity of outcome measures used to evaluate 
NAS management may have impeded the synthesis of evidence and limited its 
widespread adoption (4).       
Given the increasing prevalence of substance use in pregnancy and the adverse 
impact for the neonate and family it is important to forward our understanding of non-
pharmacological management in order to optimize outcomes.  The purpose of this 
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review is to explore the non-pharmacological management of infants at risk of 
neonatal abstinence syndrome following in utero exposure to addictive substances.  
 
 
METHODS 
A systematic mixed studies review using a convergent qualitative synthesis was 
conducted (13). The aim of a convergent design is to fully explore the same topic by 
integrating both quantitative and qualitative data. The search strategy was devised 
by a specialist librarian and online electronic databases CINAHL, MEDLINE, AMED, 
PsycArticles, PsycInfo and Web of Science were searched for peer reviewed articles 
available in English. An initial time span of 10 years, January 2007 to October 2017, 
was chosen to identify current practice, and this was updated in June 2018. The 
search was conducted by two independent reviewers and the search strategy used a 
combination of the following keywords and terms: ‘neonatal abstinence syndrome’ 
OR (withdrawal) (substance* or drug or opioid or opiate) AND (infant* or newborn or 
baby or neonat* or toddler).  A manual search of reference lists of included studies 
was also conducted to identify any relevant studies that may have been missed.  
The search strategy was intended to return a breadth of studies before applying key 
definitions, inclusion and exclusion criteria to the studies.   For the purpose of this 
review key definitions were determined for NAS expression and management 
strategies.  Infants deemed at risk of NAS and those with a diagnosis of NAS due to 
intrauterine exposure were included.  Exposure to addictive substances included 
opiate substitution medication or known illicit addictive substances in pregnancy 
verified by toxicology or maternal report. Exposure to alcohol and infants with 
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iatrogenic exposure in the postnatal period were excluded. Publications were 
considered for inclusion if they were primary research and reported individual non-
pharmacological strategies or a combination of strategies within a quality 
improvement initiative. Quality improvement initiatives with pharmacotherapy as an 
adjunct to non-pharmacological management were included.   Studies with the focus 
on pharmacotherapy or the impact of infant feeding on NAS were excluded.     
 
Data analysis and extraction  
The search strategy returned 14 studies as relevant to the review. Data abstraction 
included details and frequency of the individual strategies employed, how the 
strategy was implemented, and the outcomes used in the evaluation process (Table 
1).  The frequency of each strategy was noted.  Secondly, qualitative findings were 
read, reread and revisited as necessary to ensure representation of evidence. As a 
convergent qualitative synthesis, the qualitative findings were initially extracted as 
guided by the quantitative data categories (13). Further emergent themes were 
identified, and consensus reached on their inclusion through discussion between the 
authors. The qualitative and quantitative findings were integrated as overarching 
themes and sub-themes.   
Quality appraisal 
Due to the heterogeneity of the identified studies two quality appraisal tools were 
used.  The quality improvement studies and three cohort studies were independently 
assessed for quality appraisal and risk of bias using the Quality Improvement 
Minimum Quality Criteria Set (14). The cohort studies were assessed as quality 
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improvements as they provided a package of non-pharmacological strategies in 
addition to their primary focus of rooming-in of the mother and infant.  The remaining 
studies included a number of study designs and therefore these were appraised 
using the Mixed Methods Appraisal Tool Version 11 (15).    This tool can assess 
studies of different research designs with previous work supporting its content 
validity, efficiency and reliability (16).  
 
RESULTS 
The search identified a total of 1422 citations and title screening excluded 1062. Of 
the 360 titles returned, abstract review excluded 251 studies. Full text screening of 
the remaining 109 studies excluded 95 studies, with agreement reached through 
discussion between authors. A total of 14 studies remained and were included in the 
review (Figure 1).  
The included studies all originated in high resource countries including the United 
States of America (n=9) (17,18, 19,20.21.22,23,24,25), Canada (n=3) (26, 27,28), Austria (n=1) (29) 
and the United Kingdom (n=1) (30).  The quality improvement and cohort studies were 
appraised as fair to good methodologically, with all meeting a minimum of eight of 
the 16 quality content domains (Table 2).   The remaining five studies included an 
RCT (29) case series (18, 25), cohort study (22) and a phenomenology study (20).   A 
common study limitation of these was the variability of the study populations (Table 
3). 
Thematic analysis revealed three main themes with sub themes.  These were 1) 
non-pharmacological management strategies including rooming-in, consolation 
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therapy and complementary therapies, 2) implementation of non-pharmacological 
management derived from supporting family integrated care and health care 
professional training, 3) evaluation of NAS management including outcome 
measures and the use of NAS scoring systems to evaluate and guide management.   
Non-pharmacological management strategies 
Frequently adopted non-pharmacological strategies included consolation therapy 
and rooming-in of mother and baby.  Optimizing consolation therapies was 
introduced by five quality improvement initiatives (19, 21, 23, 24, 28).  All of the studies 
promoted environmental measures to minimize external stimuli of ambient noise and 
light. Parental presence was encouraged to console the infant or volunteers were 
used when parents were unavailable. Wachman et al. (23) and Grossman et al. (19) 
both emphasised consolation therapy rather than initiating pharmacotherapy when 
withdrawal symptoms escalated.  Walsh et al. (24) and Wachman et al. (23) promoted 
breastfeeding but Grossman et al. (19) only supported breastfeeding if there were no 
medical contraindications. Walsh et al. (24) recommended low lactose formula when 
breastfeeding was contraindicated but noted that despite provision of support 
measures increasing from 37.1% to 59.4%, there was a reluctance by practitioners 
to give low lactose formula or expressed breastmilk to infants.  
 
Rooming-in was the focus of 4 studies (26, 27, 28, 30) and was an integral part of all of 
the quality improvements. It was found to decrease the need for, and duration of, 
pharmacotherapy. Abrahams (26, 27) reported increased breastfeeding initiation 
following rooming-in and mothers were more likely to retain infant custody.   When 
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compared with regional data Abrahams (27) noted a longer hospitalization for the 
rooming-in cohort but this was contradicted by Saiki et al. (30) and Newman et al. (28) 
who both reported a shorter length of hospital stay. 
Complementary therapies of acupuncture, infant massage, vibrotactile stimulation 
and Reiki were less common and mainly used as part of feasibility studies. No 
adverse events were associated with non-insertion acupuncture and infants were 
considered to be less restless after sessions and for some there was a noted 
improvement in feeding quality (18). Laser acupuncture resulted in shorter duration of 
pharmacotherapy although no difference was noted in peak NAS scores (29).   Infant 
massage sessions were described by the majority of women as a positive 
experience enjoyed by both themselves and their baby and were valued as an 
opportunity to bond (20). The infant seemed to be calmed by the massage which in 
turn relaxed the mother, however this was not sustained once the session ended.    
Despite this, mothers reported that undertaking the massage empowered them as a 
parent as it gave them a ‘tool’ to aid their infant’s recovery.    Stochastic vibrotactile 
stimulation reduced neonatal activity with no adverse effects. However, the long-term 
safety of prolonged stimulation on the developing neonatal brain is unsubstantiated 
thus limiting the potential of this treatment (25).   Radziewicz et al. (22) found no 
adverse effects during Reiki sessions and noted a slight decrease in mean NAS 
scores.   
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Implementation of non-pharmacological management 
Implementing and optimizing the standard of non-pharmacological management 
focussed on both formal and informal care givers. This included supporting family 
integrated care, the use of volunteer care givers and health care professional 
training. In total eight studies implemented measures to support family integrated 
care with parents as the primary care givers. These included parental education, 
encouraging direct care delivery and facilitating bedside presence.  Newman et al. 
(28) surveyed rooming-in participants regarding their educational and support needs.  
Participants rated ‘how well was the (rooming-in) program explained’ as mean 4.7/5, 
and ‘did you feel well prepared to care for your baby’ as mean 4.8/5.  Whether they 
felt supported by practitioners was dependent on the professional discipline and 
ranged from mean 3.5 (nursing staff) to 4.9 (doctors). Positive verbatim comments 
included, 
 “We felt we could ask any questions and would receive the best information 
possible” and “I had a great experience and felt very supported”.   
Negative aspects of management included lack of practitioner understanding and 
disparities between assessors when evaluating NAS severity, 
“Nurses to have better understanding of addiction and methadone”, and “I 
wish nurses would’ve left us alone more- I didn’t like that they all scored 
different”. 
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Most studies placed the focus of parental education on identifying signs of NAS and 
the appropriate and timely implementation of consolation strategies.   Wachman et 
al. (24) introduced parental messaging to inform parents that continued bedside 
presence was expected and facilitated this by arranging local methadone dispensing 
and nominating additional caregivers to assist parents. Volunteer ‘cuddlers’ were 
appointed to console neonates when parents were unavailable.  One study 
encouraged practitioners to partner with a substance-exposed family to deliver 
parental education and foster family involvement (24). 
 
To enable practitioners to effectively implement non-pharmacological management 
professional training needs and behaviours focussed on improving inter-professional 
practices, enhancing communication, fostering a team approach and eliminating 
judgemental attitudes towards families. Practitioner understanding of substance use 
disorders and NAS was highlighted as an area for development by the majority of 
quality improvement studies.   Asti et al. (17) established an NAS taskforce to facilitate 
learning and champion change while Wachman et al. (23) disseminated new practices 
with multidisciplinary conferences and in-person and on-line education. Three 
studies (21, 24, 28) targeted changing negative practitioner behaviours, attitudes and 
distrust towards those with a substance use disorder. This included sessions on 
substance use as a chronic illness, how to work with families in addiction, non-
judgemental behaviours and trauma informed care.   Walsh et al. (24) introduced 
collaborative learning sessions with in-recovery mothers sharing their personal 
stories.  
 
MacVicar & Kelly 
Non-pharmacological management of NAS 
12 
 
Evaluation of NAS management   
The outcomes measured to evaluate NAS severity and management effectiveness 
included length of hospital stay, aspects of pharmacotherapy and withdrawal 
presentation.  NAS scoring systems were predominantly used when assessing 
pharmacotherapy although these were also found as a barrier to effective 
management.   
Length of hospital stay was the most commonly recorded outcome measure in ten 
studies with all noting a reduction in stay.  Nine studies considered the need for, and 
duration of, pharmacotherapy and all saw a decreased need for medications 
although individual studies evaluated this using differing statistical methods. NAS 
presentation as an outcome included the range and severity of withdrawal symptoms 
with Abrahams (26,27) noting the only difference between cohorts was less episodes of 
vomiting for neonates who roomed-in.   
NAS scoring systems were predominantly used when assessing pharmacotherapy 
although these were also found as a barrier to effective management. All studies 
employed an NAS scoring system to assess withdrawal severity and guide 
pharmacotherapy initiation and weaning.  Initially all six quality improvements used 
Finnegan scoring system (31) as their standard NAS assessment tool, however four 
studies found that practitioner training was required to standardize scoring and 
interpretation (17, 19, 21, 23).   Asti et al. (17) required an extensive and prolonged 
educational program to embed the assessment guidance into clinical practice before 
a decrease in length of neonatal stay occurred. Grossman et al. (19) decided not to 
use the Finnegan scoring system and developed their own approach, the ‘Eat, 
Sleep, Console’ assessment tool.  This simplified the assessment process based on 
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three parameters, the infant’s ability to eat and maintain hydration, sleep pattern, and 
be consoled. There was a noted reduction in length of stay after its implementation.   
Wachman et al. (23) initially used Finnegan scoring training then adopted the ‘Eat, 
Sleep, Console’ assessment and shared decision making for pharmacotherapy 
initiation and weaning. Holmes et al. (21) conducted family interviews to explore views 
on NAS assessment and incorporated these into the improvement process. This 
highlighted that infants were being woken or removed from the parents for 
assessment and given points for crying when they were hungry.  Implementation of 
‘infant-centred scoring’, when assessment was only undertaken when infants were 
skin-to-skin with carer, and a policy of on-demand feeding was introduced. 
Physicians also practiced a standardized approach to score interpretation with less 
reliance on numerical value and greater emphasis on quality of feeding, weight gain, 
inconsolability and sleep. 
 
DISCUSSION 
This review of 14 studies exploring the non-pharmacological management of infants 
at risk of NAS found that the most frequently employed strategies were consolation 
therapies, rooming-in of mother and baby and family integrated care.  Underpinning 
these strategies were training programs for practitioners and parents to enhance 
efficacy and implementation uniformity.  Common barriers included practitioner 
judgemental attitudes and distrust that parents would not meet the responsibilities of 
family integrated care; reluctance to promote breastfeeding; and the unreliability in 
the use of existing NAS scoring tools. The main outcomes measured were 
pharmacotherapy and length of hospital stay. The integrated findings demonstrated 
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that providing or optimizing non-pharmacological management resulted in a lesser 
need for pharmacotherapy and shorter duration of hospitalization for neonates.  
We found that quality improvement initiatives were the most popular method of 
implementing or improving compliance of non-pharmacological management. Quality 
improvement cycles offer a number of benefits when implementing change (32). Their 
reactive nature allows prompt identification of barriers and the process of continual 
reassessment allows strategies to be tailored to the specific challenges and local 
context.   However, this can also be a limitation for transferability and replication of 
the quality improvement to other settings and impacts on the strength of the 
evidence to influence practice.  It is suggested that stakeholders should exercise 
caution when considering the direct application of a quality improvement project to 
their clinical setting and a baseline needs assessment is recommended.  
A number of the quality initiatives encouraged family integrated care and equipped 
parents to deliver consolation therapy.  Involving families in shared care and decision 
making can reduce parental stress, facilitate family attachment and improve 
practitioner/ parent relations (33).  Valuing parents as direct care givers has been 
shown to positively impact on self-efficacy and promote parenting skills (34). Previous 
research identifies that a negative influence on maternal perceptions of self-worth is 
the feeling of guilt and responsibility associated with substance use in pregnancy (35).  
This review, however, highlighted that family integrated care was not wholly 
endorsed and was met with resistance by some practitioners.  Several studies noted 
practitioner distrust of parental commitment to meet infant care needs and parents 
reported feeling judged by health care personnel. There is an acknowledged culture 
of stigmatisation towards those with a substance use disorder within the maternity 
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setting and this can impede the development of a collaborative relationship between 
practitioners and families (12, 36).   The promotion and acceptance of new practices 
revolves around changing behaviours and attitudes.    In this review it was 
recognized that embedding respectful care was a priority to both support and 
empower the families while influencing practitioner perceptions of substance use 
disorders.   
Breastfeeding and the provision of breastmilk containing substitution medication is 
well-evidenced as a supportive practice which improves neonatal outcomes and 
increases maternal satisfaction (6, 35).  In the review only three quality initiatives 
encouraged breastfeeding and there was suboptimal practitioner compliance to 
giving expressed breast milk when mothers were not present.   Health care 
professionals need to be aware of evidence-based breastfeeding contraindications 
and the current safety profile of addictive substances in breastmilk to confidently and 
accurately advise women on breastfeeding, and to advocate on their behalf.   
Fundamental to the success of breastfeeding is maternal education on its specific 
benefits to alleviate neonatal withdrawal, support to initiate and establish lactation 
and the acceptance to express and discard milk after illicit substance use (6).     
  
The most frequently reported outcomes measures were the need for 
pharmacotherapy and length of hospital stay.  Pharmacotherapy was guided by NAS 
assessment tools and the review identified the poor application and subjectivity of 
the Finnegan scoring system as a barrier to progressing infants for discharge home. 
A number of the studies discontinued use of the Finnegan score and adopted a 
simplified system based on three parameters of eat, sleep, console. Within the 
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neonatal literature it has been queried whether the Finnegan score is still a suitable 
assessment tool given that the drug profile of intrauterine exposure has changed 
significantly since its development in 1975 (1,6).    Using the duration of hospital stay 
as an appropriate outcome measure for an infant at risk of NAS is also debatable.  
Length of stay varies significantly between centres due to factors not related to NAS, 
including social and maternal issues and institutional discharge policies.  Outpatient 
and at-home weaning programs may shorten in-hospital duration but can prolong 
duration of pharmacotherapy (37). Without a consensus on what are the predominant 
NAS outcomes, and how to define and assess these, comparison of research 
studies will remain problematic and impede our understanding and treatment of 
NAS.  
Strengths and Limitations 
 A key strength of our review is the integration of mixed studies into a comprehensive 
account of current non-pharmacological management.  This provides evidence on an 
aspect of NAS care which has long been neglected or poorly applied.  
A number of limitations should be acknowledged when interpreting the study 
findings. The review was restricted to English language only which may have 
reduced the number of retrieved, and potentially relevant, studies. The heterogeneity 
of the sources did not allow meta-analysis of the findings and resulted in a narrative 
review. Some of the study populations included all neonates exposed to intrauterine 
addictive substances without taking account of different gestations, type and length 
of exposure or infant feeding method. All of these factors can influence the 
expression of NAS and may impact the outcomes assessed. However, this variability 
is representational of clinical practice and frequently information of substance 
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exposure is limited with the interaction between polysubstance use unknown and 
unpredictable.  
 CONCLUSIONS 
Non-pharmacological management has been a neglected aspect of NAS care, and 
the current plethora of quality improvement initiatives and complementary therapies 
are timely and welcome.  Whilst the quality improvements demonstrate improved 
outcomes the review cannot draw an overall conclusion of the applicability of 
individual initiatives due to the limitations noted.   Quality improvements are context 
driven and may be uniquely tailored to their setting therefore their applicability should 
be considered in relation to a local needs assessment.  Recommendations for 
clinical practice include implementation of family integrated care, targeted 
practitioner education program on non-judgemental attitudes and the promotion and 
support of breastfeeding for women with a substance use disorder. Future research 
should focus on defining core outcome measures for NAS assessment to allow 
studies to be synthesized and thus forward our understanding to enhance and 
improve outcomes.   
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Table 1: Characteristics of included studies of non-pharmacological management of neonatal abstinence syndrome. 
Author 
(Year) 
Country  
Method 
 
Participants 
Intervention & 
Implementation 
Findings/outcomes 
Abrahams et 
al.  (26) 
(2007) 
Canada 
Retrospective cohort review  
Intervention: n=32 maternal 
addiction service & rooming- in  
Control: n=36 no addiction service & 
infant to NICU  
Historic comparison: n=38 addiction 
service & infant to NICU  
-rooming-in 
- maternal education on infant care and signs of 
NAS 
 
  
Intervention decreased pharmacotherapy v comparison 
([RR] 0.40, 95%[CI] 0.20 to 0.78) and control ([RR] 0.39, 
95%[CI] 0.20 to 0.75). 
Intervention group shortest length of stay. 
Intervention increased maternal custody of infant v control 
([RR] 1.52, 95%[CI] 1.15 to 2.53) v comparison ([RR] 2.23, 
95%[CI] 1.43 to 3.98). 
Abrahams et 
al. (27) 
(2010) 
Canada 
Retrospective cohort review 
Intervention: n=355 NAS infants 
rooming-in 
control: n=597 NAS infants 
-rooming-in  
-maternal education on infant care and signs of 
NAS 
  
Intervention decreased odds of NICU admission, increased 
breastfeeding initiation but not sustained at discharge, no 
difference in NAS severity, increased maternal custody.  
Length of stay intervention mean 21 v control 11 days. 
Asti et al. (17) 
(2015) 
USA 
Quality improvement  
Baseline n=23 
Total n=92 NAS infants  
-multidisciplinary taskforce  
-standardize assessment and pharmacotherapy 
protocol 
Length of stay reduced from 36 to 18 days and no 
readmissions for NAS within 30 days. 
Filippelli et al. 
(18) (2012) 
USA 
Retrospective case series  
n=54 NAS infants with 92 sessions in 
total  
Non-insertion acupuncture Restless infants calmed during session. No adverse events 
of changed vital signs, bruising, rash. 8 infants ‘better 
feeding’ or increased calorific intake. 
Grossman et 
al. (19) (2017) 
USA 
Quality improvement  
 
n=287 NAS infants 
 
-optimize non-pharmacological care 
 -family integrated care 
-standardize assessment and pharmacotherapy 
protocol 
Length of stay decreased from 22.4 to 5.9 days, morphine 
use decreased 98% to 14% and hospital cost decreased 
post intervention.  
Hahn et al. (20) 
 (2018) 
USA 
Phenomenology study with thematic 
analysis. 
n=8 mother and infant dyad. 
Infant massage 
 
Mothers trained to perform infant massage 
Maternal empowerment, sessions encouraged enjoyment 
and bonding, mother and infant experienced sessions as 
calm and comforting. 
Holmes et al. 
(21) 
(2016) 
USA 
Quality improvement  
 
N=207 NAS infants 
 
-optimize non-pharmacological care 
 -family integrated care 
-rooming-in 
-standardize assessment and pharmacotherapy 
protocol  
-volunteer baby carers 
Morphine decrease 46% to 27%, phenobarbital decreased   
13% to 2%. Length of stay 16.9 days to 12.3 days and costs 
reduced. 
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Newman et al. 
(28) 
(2015) 
Canada 
Quality improvement  
 
Pre-intervention n= 24   
Intervention n=21  
 
-parental education non-pharmacological care 
-low stimuli room  
-assessment scoring training  
 -community support 
Pharmacotherapy reduced 83.3% to 14.3%, length of stay 
reduced 25 to 8 days. Breastfeeding initiation 78% and 
86% duration 2.5 months. Maternal questionnaire-
n=14/21, 100% satisfaction and rooming- in rated 
favourably.  
Radziewicz et 
al. (22) 
(2018) 
USA 
Pilot cohort study 
 
n=14 infant pharmacotherapy  
n= 16 non-treated infants  
Reiki sessions No adverse events during reiki: heart rate statistically 
significant decrease, oxygen no change, mean NAS score 
no change. 
Raith et al. (29) 
(2015) 
Austria 
RCT  
Total n=28 NAS infants, 
Intervention n=14 / control n=14 
Laser acupuncture 
 
Intervention shorter median duration of pharmacotherapy 
and reduced length of stay.  
Saiki et al. (30) 
(2010) 
UK 
Retrospective cohort study 
Intervention n=18 infants  
Control n=42 infants in NICU 
Rooming-in  Intervention reduced pharmacotherapy 11% v 45% and 
reduced duration mean 7.3 v 12.7 days, shorter length of 
stay mean 15.9 v 19.8 days. 
Wachman et 
al. (23) (2018) 
USA 
Quality improvement  
 
n=240 NAS infants 
 
- optimize non-pharmacological care 
 -family integrated care 
-rooming-in 
-standardize assessment and pharmacotherapy 
protocol 
-Eat, Sleep, Console assessment   
-cuddler programme 
Total length of stay reduced mean 17.5 days v 11.6 days 
and pharmacotherapy reduced mean 17.4 days to 11.3 
days 
 
 
Walsh et al. (24) 
(2018) 
USA 
Quality improvement  
 
Intervention: n=3266 NAS infants.  
- optimize non-pharmacological care 
 -family integrated care 
-rooming-in 
-promote breastfeeding 
-standardize assessment and pharmacotherapy 
protocol 
-trauma informed care 
Pharmacotherapy decreased 33.8 days to 21.3 days and 
length of stay decreased 13.4 days to 12 days. 
Zuzarte et al. 
(25) 
(2017) 
USA 
Prospective within subject case 
series  
N=26 NAS infants  
Stochastic vibrotactile stimulation- 1 session per 
infant 
Fewer movements and 35% reduced activity, respiratory 
rate stabilised, reduced heart rate, no adverse effect on 
oxygen saturation or temperature 
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Table 2: Appraisal of Quality Improvement studies using the Quality Improvement-Minimum Quality Criteria Set (14) 
Minimum Quality Criteria Set Abraham 
et al. 
2007 
Abraham 
et al. 
2010 
Asti 
et al. 
2015 
 
Grossman 
et al. 
2017 
Holmes 
et al. 
2016 
Newman 
et al. 
2015 
Saiki 
et al. 
2010 
Wachman 
et al. 
2018 
Walsh 
et al. 
2018 
Organisational motivation N Y Y Y Y  Y Y Y Y 
Intervention rationale Y N Y Y Y Y Y Y Y 
Intervention description Y N Y Y Y Y Y Y Y 
Organisational characteristics Y Y Y Y Y Y N Y Y 
Implementation Y N Y Y Y Y Y Y Y 
Study design Y Y Y Y Y Y Y Y Y 
Comparator Y Y N N N Y Y Y N 
Data source Y Y Y Y Y Y Y Y Y 
Timing Y Y Y Y Y Y Y Y Y 
Adherence/fidelity N N N Y N Y N Y Y 
Health outcomes Y Y Y Y N Y Y Y Y 
Organisational readiness N N N Y N N N Y Y 
Penetration/reach N N N N N N N N N 
Sustainability N N Y Y N N N Y Y 
Spread Y N N N N N Y N N 
Limitations Y Y Y Y Y Y Y Y Y 
Appraisal score 11/16 8/16 11/16 13/16 9/16 12/16 11/16 14/16 13/16 
 fair poor fair good poor fair fair good good 
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Table 3: Appraisal of studies using the Mixed Methods Appraisal Tool (15) 
  Hahn 
et al.  
2016 
 
Zuzarte 
et al.  
2017  
Raith 
et al.  
2016 
Radziewicz 
et al.  
2018 
Fillippelli 
et al. 
 2012 
Screening  
questions   
Are there clear qualitative and/or quantitative research objective? Y Y Y Y Y 
Do the collected data allow address the research objective? Y Y Y Y Y 
Qualitative 1.1. Are the sources of qualitative data relevant to address the research 
objective?  
Y Y    
1.2. Is the process for analysing qualitative data relevant to address 
research objective?       
Y Y    
1.3. Is appropriate consideration given to how findings relate to the 
context in which the data were collected?     
X N    
1.4. Is appropriate consideration given to how findings relate to 
researchers’ influence 
N Y    
Quantitative 
 randomized 
controlled  
(trials) 
2.1. Is there a clear description of the randomization/ sequence 
generation?   
  N N  
2.2. Is there a clear description of the allocation concealment?    Y Y  
2.3. Are there complete outcome data (80% or above)?       Y Y  
2.4. Is there low withdrawal/drop-out (below 20%)?   Y Y  
Quantitative 
descriptive  
 
4.1. Is the sampling strategy relevant to address the quantitative research 
question?      
    Y 
4.2. Is the sample representative of the population understudy?          Y 
4.3. Are measurements appropriate (clear origin, validity known, standard 
instrument)?      
    Y 
4.4. Is there an acceptable response rate (60% or above)?        Y 
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